Clinical Trial

The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

Study acronym: FAME 1 EYE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the potential benefits of 145 mg of daily fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative diabetic retinopathy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2011-03-21; most recent amendment 2026-01-15.
Status change: Recruiting → Active, Not Recruiting 2026-01-15
Status change: Not Yet Recruiting → Recruiting 2019-09-19
Trial Details
NCT Number NCT01320345
Lead Sponsor University of Sydney
Collaborators: National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc
Conditions Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
Enrollment 412 participants
Start Date 2016-11-03
Primary Completion 2026-08-28 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20